| HOME >> BIOLOGY >> TECHNOLOGY |
Dr Andrew Cuthbertson, Director of R&D at CSL said, "The G-CSF inflammatory disease project is an excellent example of the strength of Australian medical research. We look forward to a continuing collaboration with our academic colleagues as we take this program into early stage development."
About MuriGen Therapeutics
MuriGen Therapeutics is an Australian-based drug discovery and development company established by the Walter and Eliza Hall Institute of Medical Research and four of its leading scientists. MuriGen is building a portfolio of novel drugs for unmet medical needs across a number of therapeutic areas including arthritis, thrombocytopenia, inflammation, epilepsy and thalassemia. By leveraging its proprietary drug discovery platform, MuriGen Therapeutics is working towards the validation of novel drug targets that have the potential to provide significant benefits for researchers, health care practitioners, and patients. Further information about MuriGen Therapeutics can be found at http://www.murigen.com.au
About WEHI
The Walter and Eliza Hall Institute of Medical Research (WEHI) is one
of the world's leading medical research centres. WEHI's international
reputation has been built upon major contributions to immunology,
haematology, cancer, malaria and autoimmune diseases, including diabetes,
multiple sclerosis, coeliac disease and rheumatoid arthritis. Over many
decades, advances and discoveries in these areas have led to significant
benefits for patients throughout the world. WEHI is in the front line of
the biotechnology revolution, using advances in genetics, bioinformatics
and structural biology to help develop individualised therapies and more
effective drugs. Further information about WEHI can be found at
http://www.wehi.edu.au
Further information:
Dr Nick Samaras
Chief Executiv
'/>"/>
| SOURCE Walter and Eliza Hall Institute Copyright©2008 PR Newswire. All rights reserved |